Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD
Clinical trial NCT04690556 · COMPLETED
Trial details
- NCT number
- NCT04690556
- Sponsor
- Lupin Ltd.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-09-14
- Primary completion
- 2024-05-31
- Enrollment
- 600
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.